First Patient Enrolls in Phase 2 Trial of ABX464, Potential Ulcerative Colitis Treatment

First Patient Enrolls in Phase 2 Trial of ABX464, Potential Ulcerative Colitis Treatment
A first patient has been enrolled in a proof-of-concept clinical trial of ABX464 as a possible treatment for people with moderate-to-severe active ulcerative colitis, its developer, Abivax, announced in a press release. The patient was enrolled at the University Hospitals Leuven, Belgium. The trial involves 17 other centers in seven European countries besides Belgium: France, Germany, Poland, Hungary, Czech Republic, Spain

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *